CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Fludarabine
Related studies linked through entity extraction aliases.
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM
- Status
- UNKNOWN
- Phase
- PHASE1
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a
- Status
- WITHDRAWN
- Phase
- PHASE2
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT
- Status
- TERMINATED
- Phase
- PHASE1
Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Status
- RECRUITING
- Phase
- PHASE1
Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML
- Status
- COMPLETED
- Phase
- PHASE1
Immunotherapy for the Treatment of Advanced Solid Tumor
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors
- Status
- TERMINATED
- Phase
- PHASE2
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
- Status
- TERMINATED
- Phase
- PHASE2
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE2
T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1